Why Understanding Imdur Matters for Clinicians
Imdur (isosorbide mononitrate) is commonly prescribed for chronic angina and for symptom control in some patients with heart failure (StatPearls). Clinicians need to understand Imdur uses, dosage, side effects, and interactions because dosing choices and drug combinations directly affect patient safety.
Headache is the most frequent adverse effect, occurring in roughly 20–30% of patients and often prompting early discontinuation (Australian Safety & Quality). Nitrate tolerance can develop rapidly (within 24–48 hours) without a daily nitrate‑free interval (typically 10–12 hours). Rounds AI provides label‑ and guideline‑linked reminders on nitrate‑free intervals at the point of care. Excessive dosing or lack of a nitrate‑free period increases risks of hypotension and reflex tachycardia, and co‑administration with phosphodiesterase‑5 inhibitors can cause dangerous hypotension (Mayo Clinic).
A concise, evidence-linked reference at the point of care reduces guesswork and tab-hopping. Rounds AI provides concise, citation-linked answers that help clinicians verify dosing, tolerance guidance, and interactions quickly. Learn more about Rounds AI’s approach to evidence-linked medication guidance for clinical leaders evaluating point-of-care decision support.
Imdur (Isosorbide Mononitrate): Core Definition and Clinical Role
Imdur (isosorbide mononitrate) is the brand name for isosorbide mononitrate, a long‑acting organic nitrate. It belongs to the vasodilator class and relaxes vascular smooth muscle. This vasodilation lowers preload and reduces myocardial oxygen demand, which underpins its role in angina prophylaxis (FDA label).
The medication is indicated for prophylaxis of angina pectoris due to coronary artery disease. Imdur (isosorbide mononitrate ER) is indicated for the prophylaxis of angina pectoris due to coronary artery disease; it is not labeled for heart failure. Any heart‑failure use of mononitrate would be off‑label; guideline‑supported nitrate therapy in HFrEF is typically isosorbide dinitrate (often with hydralazine) (DailyMed label). Imdur is formulated as oral, extended‑release tablets designed for sustained nitrate exposure.
Efficacy data from placebo‑controlled studies show improved exercise tolerance in stable angina. Treadmill exercise duration increased about 20–25% versus placebo in reported trials, supporting its prophylactic use (TGA assessment). Because Imdur provides long‑acting nitrate coverage, it is intended for prevention rather than immediate relief of an acute anginal episode (FDA label).
Imdur is commonly dosed once daily as an extended‑release oral tablet. Clinicians should review the official prescribing information for formulation specifics and contraindications before initiating therapy (DailyMed label).
Teams using Rounds AI can access concise, citation‑linked summaries of Imdur’s FDA and DailyMed label language and trial evidence at the point of care to support clinical decision making. Rounds AI surfaces the exact label text with clickable citations so you can verify wording on dosing, safety, and interactions as you review therapy options. Learn more about Rounds AI’s approach to evidence‑linked clinical answers as you review dosing, safety, and interaction details.
Key Pharmacologic Components of Imdur
- Active ingredient: isosorbide mononitrate
- Absorption: rapid oral uptake with minimal first‑pass metabolism
- Metabolism: biotransformation to nitrate species
- Mechanism: nitric‑oxide mediated vasodilation
- Clinical effect: reduced preload and myocardial oxygen demand
Metabolites from isosorbide mononitrate facilitate NO bioactivity in the vascular wall. NO stimulates smooth muscle relaxation and causes venous and arterial vasodilation, with a greater effect on venous capacitance vessels. The net hemodynamic effect is reduced left ventricular preload and lower myocardial oxygen demand, which underlies its role in angina prevention (StatPearls; FDA label PDF).
Because the clinical effect follows NO-mediated vasodilation rather than direct inotropic change, symptom reduction is largely due to decreased cardiac wall stress and oxygen requirement. This mechanism explains why nitrates like isosorbide mononitrate are used for prophylaxis rather than acute relief alone in some regimens. Available sources focus on pharmacologic description and prescribing details but do not provide detailed quantitative NO-release figures or direct potency comparisons with other nitrates (DrugBank). For clinicians, a simple flow diagram—oral absorption → systemic conversion → NO release → venodilation ↓ preload—helps clarify the sequence at a glance.
Clinicians using Rounds AI can quickly pull the cited label and review articles that summarize these mechanistic steps at the point of care, which supports rapid verification before prescribing. The pharmacologic profile of isosorbide mononitrate favors once-daily, long-acting formulations for stable prophylaxis, a point that will be reinforced in the pharmacokinetics summary below.
- Bioavailability ~100% for immediate-release tablets (consistent systemic exposure documented in prescribing references) (DrugBank; StatPearls).
-
Half-life supports once-daily dosing (approx. 5 hours for active moiety), which aligns with extended-release formulations used for prophylaxis (UK Medicines SPC; DrugBank).
-
No significant food effect reported; consistent timing and steady-state considerations favor stable, once-daily administration for predictable clinical effect (StatPearls; UK Medicines SPC).
Together, these mechanistic and pharmacokinetic points explain why isosorbide mononitrate is suited to long-acting, prophylactic use in angina. If you want a concise, citation-linked summary tailored for clinical teams and formularies, learn more about how Rounds AI surfaces guideline and label references to support prescribing decisions.
How Imdur Works: Pharmacodynamics and Dosing Principles
Imdur’s active ingredient, isosorbide mononitrate, produces sustained nitric oxide–mediated vasodilation that reduces myocardial oxygen demand. This explains how Imdur works and its role in angina prophylaxis and chronic symptom control.
Clinicians using immediate‑release (IR) isosorbide mononitrate may start at 10 mg once daily and increase by 10 mg increments based on symptoms and tolerability, aiming for a maintenance range of 20–40 mg once daily (University of Saskatchewan clinical guide). For Imdur extended‑release (ER) labeling, follow product guidance: “Start 30–60 mg once daily in the morning; may increase to 120 mg once daily (some labels allow up to 240 mg/day based on clinical response). Ensure a daily nitrate‑free interval to limit tolerance.” A common ER regimen described in practice is one 60 mg tablet each morning, with escalation to 120 mg once daily when clinically indicated (Imdur 60 mg SPC). The extended‑release approach sustains plasma levels through the day and simplifies adherence.
A landmark clinical series found substantial angina reduction with once‑daily 60 mg dosing, supporting its long‑term anti‑anginal effect (PubMed study).
Tolerance to nitrates can develop with continuous exposure. To maintain efficacy, practitioners schedule a nitrate‑free interval, usually overnight, to allow receptor resensitization. This dosing rhythm reduces tachyphylaxis and preserves symptom control (University of Saskatchewan clinical guide).
Missing doses can quickly lower plasma nitrate levels and cause rebound angina, so adherence and consistent timing matter for patient safety (Drugs.com monograph).
When evaluating or documenting dosing plans, prioritize individual response and tolerability. Use guideline‑aligned sources and primary literature to justify titration and scheduling choices. Clinicians using Rounds AI can rapidly locate citation‑first dosing guidance from FDA labels and guideline sources to support bedside decisions. Learn more about Rounds AI’s approach to delivering evidence‑linked dosing guidance for point‑of‑care use.
Primary Clinical Indications and Use Cases for Imdur
Imdur (isosorbide mononitrate) is primarily indicated for the prophylaxis of angina pectoris due to coronary artery disease. The official prescribing information describes its use to prevent recurrent ischemic chest pain in patients with stable coronary disease (DailyMed – Imdur label). Clinicians prescribe Imdur when the goal is routine prevention rather than immediate relief of acute angina.
Imdur also has an adjunctive role in symptom management for certain patients with chronic heart failure. When vasodilator therapy is clinically appropriate, nitrate therapy can reduce cardiac workload and improve symptoms in selected patients (Cleveland Clinic – Isosorbide mononitrate extended‑release). This application is reserved for cases guided by clinical judgment and guideline-directed heart failure care.
Extended‑release isosorbide mononitrate supports once‑daily morning dosing that, when paired with an overnight low‑nitrate window, helps mitigate tolerance. The sustained‑release preparations aim to provide stable plasma levels across the day, supporting prophylactic use rather than episodic relief (Australian TGA Assessment – Imdur). Prescribers weigh dosing schedule, tolerance risk, and symptom pattern when selecting therapy.
Typical patient profiles for Imdur include adults with stable exertional angina requiring routine prevention. Some patients with chronic heart failure may receive Imdur as part of a broader vasodilator strategy, when indicated by their clinical status. For precise, up‑to‑date label language and supporting sources, consult the full prescribing information and specialty references linked above.
Rounds AI is a citation‑first, HIPAA‑aware clinical AI available on web and iOS with a 3‑day free trial—visit https://joinrounds.com to get started.
Related Nitrate Therapies, Contraindications, and Key Terminology
Imdur (isosorbide mononitrate) carries several clear contraindications that clinicians must check before prescribing. Severe hypotension and known hypersensitivity to nitrates are absolute contraindications per the product label and monographs (Imdur prescribing information; Drugs.com monograph). Structural cardiac conditions such as hypertrophic cardiomyopathy and constrictive pericarditis also warrant avoidance because nitrates can worsen hemodynamics in those settings (Drugs.com monograph).
Exercise caution in patients who are volume-depleted or already hypotensive. Concomitant use of other potent vasodilators increases the risk of symptomatic hypotension. Most importantly, phosphodiesterase‑5 (PDE‑5) inhibitors are contraindicated with nitrates because the combination can produce profound, life‑threatening hypotension (Mayo Clinic description; Drugs.com monograph). Review recent medications and counseling points before initiating therapy.
Pharmacokinetic differences matter when choosing between isosorbide mononitrate and isosorbide dinitrate. Isosorbide mononitrate (Imdur) bypasses first‑pass hepatic metabolism, producing more predictable plasma levels and enabling once‑daily dosing in many patients (StatPearls overview; Mayo Clinic description). By contrast, isosorbide dinitrate undergoes significant first‑pass metabolism and typically requires multiple daily doses because of a shorter half‑life (StatPearls overview).
Clinically, once‑daily dosing with Imdur may improve adherence and symptom control versus multiple‑dose regimens, but tolerance remains a concern. Nitrate tolerance can develop after 24–48 hours of continuous therapy; clinical guidance recommends a daily nitrate‑free interval to mitigate tolerance (StatPearls overview; Imdur prescribing information). Trials report meaningful symptom reductions with appropriately dosed isosorbide mononitrate formulations (StatPearls overview).
For busy clinical leaders balancing safety and workflow, Rounds AI helps surface concise, citation‑linked summaries of contraindications and interactions to support bedside decision making. Teams using Rounds AI can quickly verify drug interactions and pharmacokinetic distinctions when comparing nitrates. Learn more about Rounds AI’s approach to evidence‑linked pharmacology summaries at joinrounds.com.
Imdur (isosorbide mononitrate) is an oral nitrate used to prevent angina by coronary vasodilation (StatPearls). Dosing uses extended‑release formulations to maintain steady plasma levels rather than provide immediate relief. Common adverse effects include headache, hypotension, and dizziness; key interaction risks include phosphodiesterase‑5 inhibitors and other vasodilators (DailyMed – Imdur). Contraindications and monitoring depend on comorbidities and concurrent medications.
Always confirm dosing and safety with up‑to‑date labels and guideline sources such as the DailyMed Imdur label and clinical summaries like StatPearls. Rounds AI helps teams access evidence‑linked summaries and clickable sources at the point of care. Organizations using Rounds AI can strengthen clinical governance by standardizing how clinicians verify drug information. Learn more about Rounds AI's approach to evidence‑linked clinical Q&A for teams and clinical leaders.